Cue Biopharma, Inc.
CUE
$0.768
-$0.0004-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 29.31% | 21.31% | 22.86% | 5.81% | 7.94% |
| Total Depreciation and Amortization | -31.47% | -9.80% | 3.87% | -44.07% | 175.34% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | -10.00% |
| Total Other Non-Cash Items | -671.07% | -10.13% | -19.72% | 5.65% | -91.35% |
| Change in Net Operating Assets | -39.26% | -617.07% | -6,095.00% | 44.42% | -140.90% |
| Cash from Operations | 17.61% | 3.49% | 3.67% | 9.68% | -4.22% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | -- | -98.04% | -100.20% | -100.37% | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.10% | 0.00% | -- | -- | -- |
| Issuance of Common Stock | -98.84% | 93.61% | -100.00% | 764.43% | -74.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -119.49% | 114.01% | -147.60% | 506.70% | -82.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.29% | 33.63% | -236.39% | -264.25% | -128.22% |